Merus N.V. announced interim efficacy data, as of an April 13, 2021 cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of bispecific antibody zenocutuzumab (Zeno) in patients with NRG1+ cancers, presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center (MSKCC) at the 2021 ASCO Annual Meeting. The reported data are from the ongoing phase 1/2 eNRGy trial and EAP which are investigating the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer (NSCLC); and NRG1+ other solid tumors. Key findings in the presentation include: Enrollment of 61 patients with NRG1+ pancreatic, NSCLC, and other cancers; 47 patients were evaluable for primary analysis, with a median age of 56 (range 22-84), previously treated with a median of 2 lines of prior therapy; 45 patients were evaluable for response by local review with measurable disease and the opportunity for = 1 post-baseline tumor assessment (two patients with non-measurable disease are included in the primary analysis of 47 patients, but not included in the 45 evaluable for response); First prospective clinical validation of NRG1 fusions as actionable oncogenic drivers that may be amenable to targeted therapy with Zeno.